Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of CHS-114 in Advanced Solid Tumors
NCT05635643Phase 1Active, not recruiting
- Start
- Dec 2022
- Primary completion
- Sep 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CHS-114 in solid tumor and head and neck squamous cell carcinoma (HNSCC) (4 arms). Primary endpoints: Rate of Dose Limiting Toxicity at 21 days and Summary of adverse events at 24 months. Started Dec 2022; status: active, not recruiting.
02
Drugs
CHS-114
03
Conditions
solid tumorhead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05635643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05635643.